Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | LHCGR | P22888 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998373 | 0.98 | PAX8 (0.44) | PAX8TP53KIF11MAPTSTAT3 | |
| SCHEMBL1000909 | 0.97 | PAX8 (0.45) | PAX8TP53KIF11MAPTSTAT3 | |
| SCHEMBL998843 | 0.91 | TP53 (0.44) | PAX8TP53KIF11MAPTSTAT3 | |
| SCHEMBL998711 | 0.90 | TP53 (0.48) | PAX8TP53MAPTLMNAPOLB | |
| SCHEMBL997619 | 0.89 | TP53 (0.45) | PAX8TP53KIF11MAPTSTAT3 | |
| SCHEMBL2033427 | 0.87 | KIF11 (0.44) | PAX8TP53KIF11MAPTLMNA | |
| SCHEMBL997308 | 0.87 | ABCG2 (0.47) | PAX8TP53KIF11MAPTSTAT3 | |
| SCHEMBL997501 | 0.86 | TP53 (0.46) | PAX8TP53KIF11MAPTLMNA | |
| SCHEMBL997400 | 0.86 | PAX8 (0.42) | PAX8TP53KIF11MAPTPOLB | |
| SCHEMBL996806 | 0.86 | KIF11 (0.41) | PAX8TP53KIF11MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | claimed |
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | PAX8 4531/4885TP53 945/4885KIF11 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.